AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

People with diabetes are more prone to developing Staphylococcus aureus, a leading cause of infections and death associated ...

Identifying the cause of infection or the type of injury that has led to a ... aureus. Several new antibiotics such as linezolid, tigecycline and daptomycin, among others, are now available ...

Zuckerman is president of the National Center for Health Research and a former congressional investigator on FDA approval standards. Powers is professor of clinical medicine at George Washington ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

The type of sinus infection you have depends ... Most children will fully recover from a sinus infection without antibiotics. Antibiotics are used for severe cases of sinusitis or in children ...

Using real-time tracking, they demonstrated that nearly all Salmonella in infected tissues resist antibiotics due to slow growth, challenging long-standing theories. These findings could reshape ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Pediatr Infect Dis J. 2008;27(1):67-68. The rapid emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has required important changes in the empiric choice of ...